Noxopharm Limited (ASX:NOX)

Market Cap	27.18M
Revenue (ttm)	2.82M
Net Income (ttm)	-4.88M
Shares Out	292.24M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,000
Average Volume	78,162
Open	0.0930
Previous Close	0.0930
Day's Range	0.0920 - 0.0990
52-Week Range	0.0430 - 0.1350
Beta	-0.31
RSI	49.57
Earnings Date	Nov 24, 2025

About Noxopharm

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company als...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 7
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NOX

Financial Performance

In 2025, Noxopharm's revenue was 2.82 million, an increase of 17.52% compared to the previous year's 2.40 million. Losses were -4.88 million, 36.5% more than in 2024.